Hanmi Receives First Korea FDA Approval For Generic Of BMS’ Baraclude
This article was originally published in PharmAsia News
Executive Summary
Hanmi is the first to clear regulatory hurdles to sell the country’s best-selling hepatitis B therapy after patent expiration in 2015, though the distinction doesn’t carry the same benefits as it once did.